Array BioPharma IncFind Ratings Reports
ARRAY BIOPHARMA INC's gross profit margin for the second quarter of its fiscal year 2017 has decreased when compared to the same period a year ago. The company has grown sales and net income significantly, outpacing the average growth rates of competitors within its industry. ARRAY BIOPHARMA INC is extremely liquid. Currently, the Quick Ratio is 3.99 which clearly shows the ability to cover any short-term cash needs. ARRY managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 786.14% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY17||Q2 FY16|
|Net Sales ($mil)||44.52||35.43|
|Net Income ($mil)||-23.3||-24.16|
|Balance Sheet||Q2 FY17||Q2 FY16|
|Cash & Equiv. ($mil)||213.93||119.88|
|Total Assets ($mil)||272.2||199.92|
|Total Debt ($mil)||128.34||110.39|
|Profitability||Q2 FY17||Q2 FY16|
|Gross Profit Margin||80.84||85.11|
|Return on Assets||-36.58||0.21|
|Return on Equity||-191.34||7.18|
|Debt||Q2 FY17||Q2 FY16|
|Share Data||Q2 FY17||Q2 FY16|
|Shares outstanding (mil)||168.93||143.34|
|Div / share||0.0||0.0|
|Book value / share||0.31||0.04|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||4098602.0||6978799.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 34.86 indicates a significant premium versus the S&P 500 average of 2.98 and a significant premium versus the industry average of 13.45. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, ARRAY BIOPHARMA INC proves to trade at a premium to investment alternatives within the industry.
|ARRY NM||Peers 40.94||ARRY NM||Peers 23.70|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ARRY's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ARRY's P/CF is negative making the measure meaningless.
|ARRY NM||Peers 60.14||ARRY NA||Peers 0.53|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ARRY's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ARRY 34.86||Peers 13.45||ARRY -1575.00||Peers 169.46|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ARRY is trading at a significant premium to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, ARRY is expected to significantly trail its peers on the basis of its earnings growth rate.
|ARRY 10.67||Peers 295.21||ARRY 12.94||Peers 518.87|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ARRY is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
ARRY significantly trails its peers on the basis of sales growth